RecruitingPhase 1Phase 2NCT04634357

ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma

An Open-Label, Dose Escalation, Phase I/II Clinical Trial of ET140203 T Cells in Pediatric Subjects With Relapsed/Refractory Hepatoblastoma (HB), Hepatocellular Neoplasm-Not Otherwise Specified (HCN-NOS), or Hepatocellular Carcinoma (HCC)

Sponsor

Eureka Therapeutics Inc.

Enrollment

15 participants

Start Date

Jul 19, 2022

Study Type

INTERVENTIONAL

Conditions

Liver Cancer Metastatic Liver Cancer Liver Neoplasms Hepatocellular Carcinoma (HCC)Hepatoblastoma HEMNOS

Summary

Open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety/tolerability and determine the recommended Phase II Dose (RP2D) of ET140203 T-cells in pediatric subjects who are AFP-positive/HLA-A2-positive and have relapsed/refractory HB, HCN-NOS, or HCC.

Eligibility

Min Age: 1 YearMax Age: 21 Years

Inclusion Criteria9

Histologically confirmed HB, HCN-NOS, or HCC with serum AFP \>100ng/mL at the time of screening and following the most recent line of therapy.
Disease reoccurrence after remission following initial standard-of care (SOC) treatment (i.e., relapse) or failure of response to SOC treatment (i.e., refractory).
Age ≥ 1 year and ≤ 21 years.
Molecular Human Leukocyte Antigen (HLA) class I allele typing that confirms subject carries at least one HLA-A2 allele.
Life expectancy of \> 4 months per the Investigator's opinion.
Lansky or Karnofsky Performance Scale ≥ 70.
For enrollment to the dose-finding cohort, subjects must have at least one (1) lesion ≥ 5 mm in diameter or two (2) or more lesions ≥ 3 mm in diameter. For the dose-expansion cohort, subjects must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Child-Pugh score of A6 or better.
Adequate organ function.

Exclusion Criteria12

Recurrent HB who are candidates for complete surgical resection (e.g., isolated pulmonary relapse amendable to pulmonary metastasectomy).
Pre-existing illness including heart failure, uncontrolled pulmonary disease not cancer-related, or psychiatric illness/social situation that would limit compliance with study requirements.
Active, uncontrolled systemic bacterial, fungal, or viral infection. Subjects with Human Immunodeficiency Virus (HIV), hepatitis B, or hepatitis C are eligible provided their infection is being treated and the viral load is controlled.
Any known active malignancy (other than HB, HCN-NOS, or HCC).
Pregnant or lactating women.
Received the following within two (2) weeks of leukapheresis or within two (2) weeks of conditioning chemotherapy: cytotoxic chemotherapy, radiation, other anti-cancer therapies (including immunotherapeutic agents), immunosuppressive therapy, or systemic corticosteroids at doses greater than 5 mg/day of prednisone or equivalent doses of other corticosteroids. (Note: Topical and inhaled corticosteroids in standard doses and physiological replacement doses of corticosteroids for adrenal insufficiency are allowed).
Concurrently receiving other investigational agents, biological, chemical, or radiation therapies, while participating in the study.
Contraindication for receipt of conditioning chemotherapeutic agents including Fludarabine and Cyclophosphamide.
Active autoimmune disease requiring systemic immunosuppressive therapy.
Compromised circulation in the main portal vein, hepatic vein, or vena cava due to partial or complete obstruction which, in the opinion of the Investigator, would make the subject unsuitable for the study.
History of organ transplant.
HB, HCN-NOS, or HCC involving greater than 50% of the liver (volumetric).